2014 Korean Liver Cancer Study Group-National Cancer Center Korea Practice Guideline for the Management of Hepatocellular Carcinoma
Open accessThe DOI matches its Crossref record; 367 of the 367 references it cites were found in a registry or an index.
Abstract
The guideline for the management of hepatocellular carcinoma (HCC) was first developed in 2003 and revised in 2009 by the Korean Liver Cancer Study Group and the National Cancer Center, Korea. Since then, many studies on HCC have been carried out in Korea and other countries. In particular, a substantial body of knowledge has been accumulated on diagnosis, staging, and treatment specific to Asian characteristics, especially Koreans, prompting the proposal of new strategies. Accordingly, the new guideline presented herein was developed on the basis of recent evidence and expert opinions. The primary targets of this guideline are patients with suspicious or newly diagnosed HCC. This guideline provides recommendations for the initial treatment of patients with newly diagnosed HCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Wu, L.-W., Hu, A., Tam, N. L., Zhang, J., Lin, M. T., Guo, Z., & He, X.-S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041820 · Cited by 45 · cited 1×
“This is because the risk factors for HCC recurrence after SLT are similar to those of primary LT (236, 240).”
BackgroundRetractedNew response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534 · cited 1×
“Meanwhile, the criteria for the evaluation of nontargeted lesions are as follows (492, 494): 1) CR: Disappearance of all nontargeted lesions and normalization of tumor marker levels.”
BackgroundGRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305 · cited 3×
“Strong (1) Factors influencing the strength of the recommendation included the quality of the evidence, presumed patient-important outcomes, and cost.”
BackgroundMethodNew Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Transection of the oesophagus for bleeding oesophageal varices
Pugh, R. N. H., Murray-Lyon, I. M., Dawson, J. L., Pietroni, M. C., & Williams, R. (1973) · Journal of British Surgery · doi:10.1002/bjs.1800600817 · Cited by 7,941 · cited 1×
“Child-Pugh classification is conventionally used to preoperatively assess the safety of hepatic resection (Table 5) (91).”
MethodReporting results of cancer treatment
Miller, A. B., Hoogstraten, B., Staquet, M., & Winkler, A. (1981) · Cancer · doi:10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6 · Cited by 7,793 · cited 1×
“In oncology, tumor response was initially measured according to the 1979 World Health Organization (WHO) criteria as follows (491): 1) CR: Complete disappearance of all known disease and no new lesions determined by two observations not less than 4 weeks apart.”
MethodEarly Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer
Temel, J. S., Greer, J. A., Muzikansky, A., Gallagher, E. R., Admane, S., Jackson, V. A., Dahlin, C. M., Blinderman, C. D., Jacobsen, J., Pirl, W. F., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000678 · Cited by 7,482 · cited 1×
“The prevalence of pain in cancer patients ranges from 45% to 53% (454-456), and early aggressive palliative care including pain management could improve survival in lung cancer patients (457).”
BackgroundMazzaferro, V., Regalia, E., Doci, R., Andreola, S., Pulvirenti, A., Bozzetti, F., Montalto, F., Ammatuna, M., Morabito, A., & Gennari, L. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603143341104 · Cited by 7,186 · cited 1×
“Accordingly, they suggest those criteria for LT in patients with HCC (162).”
BackgroundA New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,936
Recommendations of the International Commission on Radiological Protection
(1961) · Postgraduate Medical Journal · doi:10.1136/pgmj.37.425.168-b · Cited by 5,862
Management of Hepatocellular Carcinoma *
Bruix, J., & Sherman, M. (2005) · Hepatology · doi:10.1002/hep.20933 · Cited by 5,857
Cheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Acute Abdomen: A Rare Case of Ruptured Hepatocellular Carcinoma
Gloor, S., Jensen, K. O., Breitenstein, S., Binkert, C. A., Angst, E., & Hetzer, F. H. (2017) · Case Reports in Gastroenterology · doi:10.1159/000463378 · Cited by 5,370
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
Lencioni, R., & Llovet, J. (2010) · Seminars in Liver Disease · doi:10.1055/s-0030-1247132 · Cited by 4,329 · cited 2×
“*Adapted from J Hepatol 2012;56:908-943 (58) and Semin Liver Dis 2010;30:52-60 (498).”
BackgroundClinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference
Bruix, J., Sherman, M., Llovet, J. M., Beaugrand, M., Lencioni, R., Burroughs, A. K., Christensen, E., Pagliaro, L., Colombo, M., & Rodés, J. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00130-1 · Cited by 4,089 · cited 1×
“To overcome these limitations, the EASL developed new criteria for HCC treatment response that take into account the degree of necrosis (496).”
MethodForner, A., Llovet, J. M., & Bruix, J. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61347-0 · Cited by 4,022
El-Serag, H. B. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1001683 · Cited by 3,529
Llovet, J. M., Real, M. I., Montaña, X., Planas, R., Coll, S., Aponte, J., Ayuso, C., Sala, M., Muchart, J., Solà, R., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08649-x · Cited by 3,494 · cited 1×
“Several RCTs and meta-analyses confirm compared to supportive treatments, TACE results in more favorable tumor response, time to progression, and survival outcomes in patients with unresectable HCC (77, 290, 291).”
ResultWhat is ‘quality of evidence’ and why is it important to clinicians?
Guyatt, G. H., Oxman, A. D., Kunz, R., Vist, G. E., Falck-Ytter, Y., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39490.551019.be · Cited by 3,250 · cited 3×
“Weak (2) Variability in preferences and values, or more uncertainty; recommendation is made with less certainty, higher cost or resource consumption.”
BackgroundMethodLok, A. S. F., & McMahon, B. J. (2007) · Hepatology · doi:10.1002/hep.21513 · Cited by 3,087
Llovet, J. M., & Bruix, J. (2003) · Hepatology · doi:10.1053/jhep.2003.50047 · Cited by 3,029 · cited 1×
“The prediction of prognosis in HCC patients is complex, because underlying liver function also affects prognosis (77, 78).”
BackgroundD'Amico, G., Garcia-Tsao, G., & Pagliaro, L. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2005.10.013 · Cited by 2,687 · cited 2×
“Several RCTs and meta-analyses confirm compared to supportive treatments, TACE results in more favorable tumor response, time to progression, and survival outcomes in patients with unresectable HCC (77, 290, 291).”
BackgroundResultLo, C.-M., Ngan, H., Tso, W.-K., Liu, C.-L., Lam, C.-M., Poon, R. T.-P., Fan, S.-T., & Wong, J. (2002) · Hepatology · doi:10.1053/jhep.2002.33156 · Cited by 2,613 · cited 1×
“Several RCTs and meta-analyses confirm compared to supportive treatments, TACE results in more favorable tumor response, time to progression, and survival outcomes in patients with unresectable HCC (77, 290, 291).”
ResultLamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease
Liaw, Y.-F., Sung, J. J. Y., Chow, W. C., Farrell, G., Lee, C.-Z., Yuen, H., Tanwandee, T., Tao, Q.-M., Shue, K., Keene, O. N., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033364 · Cited by 2,266
Yao, F. Y., Ferrell, L., Bass, N. M., Watson, J. J., Bacchetti, P., Venook, A., Ascher, N. L., & Roberts, J. P. (2001) · Hepatology · doi:10.1053/jhep.2001.24563 · Cited by 2,262 · cited 2×
“5 cm and the sum of diameters < 8 cm (183).”
BackgroundHealth Risks from Exposure to Low Levels of Ionizing Radiation:: BEIR VII Phase 2
Earth, D. O. (2006) · CERN Document Server (European Organization for Nuclear Research) · Cited by 2,190
Preface, Executive Summary and Glossary
(2007) · Annals of the ICRP · doi:10.1016/j.icrp.2007.10.003 · Cited by 2,106
Mazzaferro, V., Llovet, J. M., Miceli, R., Bhoori, S., Schiavo, M., Mariani, L., Camerini, T., Roayaie, S., Schwartz, M. E., Grazi, G. L., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70284-5 · Cited by 2,045
Larson, A. M., Polson, J., Fontana, R. J., Davern, T. J., Lalani, E., Hynan, L. S., Reisch, J. S., Schiødt, F. V., Ostapowicz, G., Shakil, A. O., et al. (2005) · Hepatology · doi:10.1002/hep.20948 · Cited by 1,926
Prevalence of pain in patients with cancer: a systematic review of the past 40 years
van den Beuken-van Everdingen, M. H. J., de Rijke, J. M., Kessels, A. G., Schouten, H. C., van Kleef, M., & Patijn, J. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm056 · Cited by 1,923 · cited 1×
“The prevalence of pain in cancer patients ranges from 45% to 53% (454-456), and early aggressive palliative care including pain management could improve survival in lung cancer patients (457).”
BackgroundGoing from evidence to recommendations
Guyatt, G. H., Oxman, A. D., Kunz, R., Falck-Ytter, Y., Vist, G. E., Liberati, A., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39493.646875.ae · Cited by 1,810 · cited 2×
“The evidence and recommendations were graded according to the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system with minor modifications (1-4).”
MethodGrading quality of evidence and strength of recommendations for diagnostic tests and strategies
Schünemann, H. J., Oxman, A. D., Brozek, J., Glasziou, P., Jaeschke, R., Vist, G. E., Williams, J. W., Kunz, R., Craig, J., Montori, V. M., et al. (2008) · BMJ · doi:10.1136/bmj.39500.677199.ae · Cited by 1,782
(2011) · Hepatogastroenterology · doi:10.5754/hge11589 · Cited by 1,756
Panahi, M., Naderi, M., Morteza, T. S., & Parizadeh, S. M. J. (2007) · Cited by 1,722
Llovet, J. M., Fuster, J., & Bruix, J. (1999) · Hepatology · doi:10.1002/hep.510300629 · Cited by 1,708 · cited 3×
“The 5-year recurrence rate following hepatic resection is up to 70% and is due to intrahepatic metastases and/or de novo carcinogenesis (96, 423, 499, 500).”
BackgroundDesign and Endpoints of Clinical Trials in Hepatocellular Carcinoma
Llovet, J. M., Di Bisceglie, A. M., Bruix, J., Kramer, B. S., Lencioni, R., Zhu, A. X., Sherman, M., Schwartz, M., Lotze, M., Talwalkar, J., et al. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn134 · Cited by 1,653 · cited 1×
“Furthermore, mRECIST criteria were first proposed by a panel of experts (497, 498); this proposal is based on the fact that the diameter of the target lesions with viable tumors should guide all assessments.”
BackgroundImamura, H., Matsuyama, Y., Tanaka, E., Ohkubo, T., Hasegawa, K., Miyagawa, S., Sugawara, Y., Minagawa, M., Takayama, T., Kawasaki, S., et al. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00360-4 · Cited by 1,589 · cited 4×
“As there recurrence rate 5 years after curative resection for HCC is very high at 70% (see “Liver Resection” section) (142, 423, 424), an effective adjuvant therapy is urgently required.”
BackgroundInfluentialLammer, J., Malagari, K., Vogl, T., Pilleul, F., Denys, A., Watkinson, A., Pitton, M., Sergent, G., Pfammatter, T., Terraz, S., et al. (2010) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-009-9711-7 · Cited by 1,557 · cited 21×
“Downstaging of HCC with TACE may be possible in 24–63% of cases (178, 196, 202, 203).”
BackgroundMethodInfluentialEASL clinical practice guidelines management of chronic hepatitis B
张学武, & Li, X. (2009) · Inter J Epidemiol Infect Dis · doi:10.3760/cma.j.issn.1673-4149.2009.04.001 · Cited by 1,506
Randomized controlled trial of screening for hepatocellular carcinoma
Zhang, B.-H., Yang, B.-H., & Tang, Z.-Y. (2004) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-004-0552-0 · Cited by 1,496 · cited 1×
“The cost-effectiveness and survival benefit of patients with early HCC detected in surveillance programs have been documented in previous studies (44).”
BackgroundChen, M.-S., Li, J.-Q., Zheng, Y., Guo, R.-P., Liang, H.-H., Zhang, Y.-Q., Lin, X.-J., & Lau, W. Y. (2006) · Annals of Surgery · doi:10.1097/01.sla.0000201480.65519.b8 · Cited by 1,432 · cited 1×
“There were no significant differences in the survival outcomes between the two treatments in one RCT for solitary HCC < 5 cm and another RCT for single or double HCCs < 4 cm (262, 263).”
BackgroundBenefits and costs, an eternal balance
Dixon, A. K. (2007) · Annals of the ICRP · doi:10.1016/j.icrp.2007.09.001 · Cited by 1,355
Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma
El-serag, H. B., Tran, T., & Everhart, J. E. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.10.065 · Cited by 1,230 · cited 1×
“liver disease, associations between diabetes and obesity, with HCC were recently reported (39, 40).”
BackgroundLlovet, J. M., Bustamante, J., Castells, A., Vilana, R., Del Carmen Ayuso, M., Sala, M., Brú, C., Rodés, J., & Bruix, J. (1999) · Hepatology · doi:10.1002/hep.510290145 · Cited by 1,190 · cited 1×
“, liver resection, liver transplantation [LT], and percutaneous ethanol injection) showed a 3-year survival rate of 28% without any treatment for HCC (11).”
BackgroundPreston, D. L., Shimizu, Y., Pierce, D. A., Suyama, A., & Mabuchi, K. (2003) · Radiation Research · doi:10.1667/rr3049 · Cited by 1,172
World Review of Laparoscopic Liver Resection—2,804 Patients
Nguyen, K. T., Gamblin, T. C., & Geller, D. A. (2009) · Annals of Surgery · doi:10.1097/sla.0b013e3181b0c4df · Cited by 1,136 · cited 1×
“Accordingly, its efficacy and safety should be evaluated further (123).”
BackgroundLivraghi, T., Meloni, F., Di Stasi, M., Rolle, E., Solbiati, L., Tinelli, C., & Rossi, S. (2008) · Hepatology · doi:10.1002/hep.21933 · Cited by 1,103
Salem, R., Lewandowski, R. J., Mulcahy, M. F., Riaz, A., Ryu, R. K., Ibrahim, S., Atassi, B., Baker, T., Gates, V., Miller, F. H., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.09.006 · Cited by 1,074 · cited 2×
“7 months, respectively; the difference was also statistically significant (312, 313).”
BackgroundBelghiti, J., Hiramatsu, K., Benoist, S., Massault, P. P., Sauvanet, A., & Farges, O. (2000) · Journal of the American College of Surgeons · doi:10.1016/s1072-7515(00)00261-1 · Cited by 1,051 · cited 1×
“However, Child-Pugh classification is an insufficient preoperative indicator of operability, because many patients can remain in Child-Pugh class A despite advanced cirrhosis (92, 93).”
BackgroundThe general rules for the clinical and pathological study of primary liver cancer
Liver Cancer Study Group of Japan (1989) · The Japanese Journal of Surgery · doi:10.1007/bf02471576 · Cited by 1,037
Forner, A., Vilana, R., Ayuso, C., Bianchi, L., Solé, M., Ayuso, J. R., Boix, L., Sala, M., Varela, M., Llovet, J. M., et al. (2008) · Hepatology · doi:10.1002/hep.21966 · Cited by 1,032 · cited 2×
“The diagnostic sensitivity of fine-needle aspiration cytology, fine-needle aspiration biopsy, and core needle biopsy are reported to be 67% to 93% but much lower in patients with small HCC < 2 cm or targeting problems (63, 64).”
BackgroundClavien, P.-A., Lesurtel, M., Bossuyt, P. M., Gores, G. J., Langer, B., & Perrier, A. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70175-9 · Cited by 1,026
Omata, M., Lesmana, L. A., Tateishi, R., Chen, P.-J., Lin, S.-M., Yoshida, H., Kudo, M., Lee, J. M., Choi, B. I., Poon, R. T. P., et al. (2010) · Hepatology International · doi:10.1007/s12072-010-9165-7 · Cited by 1,026 · cited 2×
“org of HCC on the basis of these small nodules (45, 48, 62).”
BackgroundLencioni, R. A., Allgaier, H.-P., Cioni, D., Olschewski, M., Deibert, P., Crocetti, L., Frings, H., Laubenberger, J., Zuber, I., Blum, H. E., et al. (2003) · Radiology · doi:10.1148/radiol.2281020718 · Cited by 998 · cited 5×
“The reported rates of tumor necrosis after PEIT range between 66% and 100% (249-251, 259).”
BackgroundResultInfluentialVarela, M., Real, M. I., Burrel, M., Forner, A., Sala, M., Brunet, M., Ayuso, C., Castells, L., Montañá, X., Llovet, J. M., et al. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2006.10.020 · Cited by 941 · cited 10×
“Downstaging of HCC with TACE may be possible in 24–63% of cases (178, 196, 202, 203).”
BackgroundInfluentialShiina, S., Teratani, T., Obi, S., Sato, S., Tateishi, R., Fujishima, T., Ishikawa, T., Koike, Y., Yoshida, H., Kawabe, T., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.04.009 · Cited by 877 · cited 5×
“Initial complete tumor necrosis rates on imaging studies are reported to exceed 96% and if RFA procedures are repeated for residual viable tumors, a complete tumor necrosis rate of almost 100% can be achieved (250).”
BackgroundResultInfluentialLencioni, R., Cioni, D., Crocetti, L., Franchini, C., Pina, C. D., Lera, J., & Bartolozzi, C. (2005) · Radiology · doi:10.1148/radiol.2343040350 · Cited by 867 · cited 3×
“RFA and percutaneous ethanol injection therapy (PEIT) are the current standard local therapies, while others such as microwave ablation, laser ablation, cryoablation, acetic acid injection therapy, and high-intensity focused ultrasound are currently undergoing clinical trials.”
BackgroundInfluentialLiver Resection Versus Transplantation for Hepatocellular Carcinoma in Cirrhotic Patients
Bismuth, H., Chiche, L., Adam, R., Castaing, D., Diamond, T., & Dennison, A. (1993) · Annals of Surgery · doi:10.1097/00000658-199308000-00005 · Cited by 865 · cited 1×
“However, this resulted in the identification of the best candidates, and subsequent studies with highly specific groups of patients report a 5-year disease-free survival rate of 74% (160, 161).”
BackgroundNishiguchi, S., Kuroki, T., Nakatani, S., Morimoto, H., Takeda, T., Nakajima, S., Shiomi, S., Seki, S., Kobayashi, K., & Otani, S. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91739-x · Cited by 857
Portolani, N., Coniglio, A., Ghidoni, S., Giovanelli, M., Benetti, A., Tiberio, G. A. M., & Giulini, S. M. (2006) · Annals of Surgery · doi:10.1097/01.sla.0000197706.21803.a1 · Cited by 857 · cited 2×
“recurrence, include cirrhosis, high serum HBV DNA level, and active hepatitis (59, 142-148).”
BackgroundTakayama, T., Sekine, T., Makuuchi, M., Yamasaki, S., Kosuge, T., Yamamoto, J., Shimada, K., Sakamoto, M., Hirohashi, S., Ohashi, Y., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02654-4 · Cited by 847 · cited 1×
“A study of activated immune cells derived from patients shows a 15% decrease in the 3-year recurrence rate compared to that of the control group (428).”
ResultHuang, J., Yan, L., Cheng, Z., Wu, H., Du, L., Wang, J., Xu, Y., & Zeng, Y. (2010) · Annals of Surgery · doi:10.1097/sla.0b013e3181efc656 · Cited by 844
Poon, R. T.-P., Fan, S. T., Lo, C. M., Liu, C. L., & Wong, J. (2002) · Annals of Surgery · doi:10.1097/00000658-200203000-00009 · Cited by 844 · cited 1×
“Salvage Liver Transplantation Salvage liver transplantation (SLT) is promoted as a potential curative treatment strategy for HCC recurrence following primary liver resection with curative intent (230).”
BackgroundKudo, M., Izumi, N., Kokudo, N., Matsui, O., Sakamoto, M., Nakashima, O., Kojiro, M., Makuuchi, M., & for the HCC Expert Panel of Japan Society of Hepatology (2011) · Digestive Diseases · doi:10.1159/000327577 · Cited by 825 · cited 4×
“, hypervascularity in the arterial phase and washout in the portal or delayed phase) for liver nodules ≥ 1 cm in diameter (45, 62, 67).”
BackgroundInfluentialBujold, A., Massey, C. A., Kim, J. J., Brierley, J., Cho, C., Wong, R. K. S., Dinniwell, R. E., Kassam, Z., Ringash, J., Cummings, B., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.1659 · Cited by 820 · cited 1×
“In most centers, hypofractionated radiotherapy including stereotactic ablative radiation therapy is used to treat patients with Child-Pugh A or superb B liver function and adequate normal liver volume; the 2-year local control and survival rates are reported to range from 70% to 100% and 50% to 75%, respectively (319-…”
BackgroundSINGAL, A., VOLK, M. L., WALJEE, A., SALGIA, R., HIGGINS, P., ROGERS, M. A. M., & MARRERO, J. A. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.04014.x · Cited by 819 · cited 1×
“, abdominal ultrasound and serum α-fetoprotein [AFP]) is warranted in these high-risk groups (42, 43).”
BackgroundNovel advancements in the management of hepatocellular carcinoma in 2008
Llovet, J. M., & Bruix, J. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.01.022 · Cited by 815
Takayasu, K., Arii, S., Ikai, I., Omata, M., Okita, K., Ichida, T., Matsuyama, Y., Nakanuma, Y., Kojiro, M., Makuuchi, M., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.05.021 · Cited by 810
Long-Term Follow-up of HBeAg-Positive Patients Treated with Interferon Alfa for Chronic Hepatitis B
Niederau, C., Heintges, T., Lange, S., Goldmann, G., Niederau, C. M., Mohr, L., & Häussinger, D. (1996) · New England Journal of Medicine · doi:10.1056/nejm199605303342202 · Cited by 803
Cheng, A.-L., Kang, Y.-K., Lin, D.-Y., Park, J.-W., Kudo, M., Qin, S., Chung, H.-C., Song, X., Xu, J., Poggi, G., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.8372 · Cited by 777 · cited 1×
“The median survival of patients treated with sorafenib was consistently reported to be approximately 10 months in the following 3 randomized controlled phase III trials testing novel molecular targeted agent in which sorafenib treatment was the control group (376-378).”
BackgroundJohnson, P. J., Qin, S., Park, J.-W., Poon, R. T. P., Raoul, J.-L., Philip, P. A., Hsu, C.-H., Hu, T.-H., Heo, J., Xu, J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.4410 · Cited by 772 · cited 1×
“The median survival of patients treated with sorafenib was consistently reported to be approximately 10 months in the following 3 randomized controlled phase III trials testing novel molecular targeted agent in which sorafenib treatment was the control group (376-378).”
BackgroundFeng, K., Yan, J., Li, X., Xia, F., Ma, K., Wang, S., Bie, P., & Dong, J. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.05.007 · Cited by 767 · cited 2×
“There were no significant differences in the survival outcomes between the two treatments in one RCT for solitary HCC < 5 cm and another RCT for single or double HCCs < 4 cm (262, 263).”
BackgroundMicrowave Tumor Ablation: Mechanism of Action, Clinical Results, and Devices
Lubner, M. G., Brace, C. L., Hinshaw, J. L., & Lee, F. T. (2010) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2010.04.007 · Cited by 765 · cited 1×
“In addition, effective ablation can be expected even for tissues with low electrical conductivity, and the simultaneous application of multiple electrodes is technically feasible with this technique (280, 281).”
BackgroundRadiation-Related Cancer Risks at Low Doses among Atomic Bomb Survivors
Pierce, D. A., & Preston, D. L. (2000) · Radiation Research · doi:10.1667/0033-7587(2000)154[0178:rrcral]2.0.co;2 · Cited by 757 · cited 1×
“Diagnostic X-ray Radiation Exposure Dose and Risk of Dynamic CT in HCC Patients A study of low-dose radiation in atomic bomb survivors indicates a significant increase in cancer risk even from acute 10–50 mSv radiation exposure (68).”
BackgroundIshizawa, T., Hasegawa, K., Aoki, T., Takahashi, M., Inoue, Y., Sano, K., Imamura, H., Sugawara, Y., Kokudo, N., & Makuuchi, M. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.02.091 · Cited by 754
Radiation-Associated Liver Injury
Pan, C. C., Kavanagh, B. D., Dawson, L. A., Li, X. A., Das, S. K., Miften, M., & Ten Haken, R. K. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.06.092 · Cited by 753 · cited 1×
“For hypofractionated EBRT consisting of ≤ 10 fractions, the normal liver volume receiving < 15 Gy must be ≥ 700 mL (317) and the dose to the normal liver volume excluding the tumor must be limited to ≤ 28 Gy (corrected to 2 Gy per fraction-equivalent dose) (318).”
BackgroundExtrahepatic Metastases of Hepatocellular Carcinoma
Katyal, S., Oliver, J. H., Peterson, M. S., Ferris, J. V., Carr, B. S., & Baron, R. L. (2000) · Radiology · doi:10.1148/radiology.216.3.r00se24698 · Cited by 742 · cited 1×
“Extrahepatic recurrence develops in 15–37% of cases after HCC resection, most frequently in the lungs followed by the abdominal cavity and bones (155).”
BackgroundRadiofrequency Ablation for Hepatocellular Carcinoma: 10-Year Outcome and Prognostic Factors
Shiina, S., Tateishi, R., Arano, T., Uchino, K., Enooku, K., Nakagawa, H., Asaoka, Y., Sato, T., Masuzaki, R., Kondo, Y., et al. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.425 · Cited by 724 · cited 1×
“For Child-Pugh class A cirrhotic patients with tumors < 2 cm, the 3- and 5-year overall survival rates after RFA are reported to be approximately 90% and 65–70%, respectively (247, 252, 253); meanwhile, those for tumors 2–5 cm are 65–75% and 50%, respectively (252, 253).”
BackgroundThe new liver allocation system: Moving toward evidence-based transplantation policy
Freeman, R. B., Wiesner, R. H., Harper, A., McDiarmid, S. V., Lake, J., Edwards, E., Merion, R., Wolfe, R., Turcotte, J., & Teperman, L. (2002) · Liver Transplantation · doi:10.1053/jlts.2002.35927 · Cited by 724
Pharmacokinetics and dosage adjustment in patients with renal dysfunction
Verbeeck, R. K., & Musuamba, F. T. (2009) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-009-0678-8 · Cited by 717
Hosaka, T., Suzuki, F., Kobayashi, M., Seko, Y., Kawamura, Y., Sezaki, H., Akuta, N., Suzuki, Y., Saitoh, S., Arase, Y., et al. (2013) · Hepatology · doi:10.1002/hep.26180 · Cited by 710
Simplified Staging for Hepatocellular Carcinoma
Vauthey, J. N., Lauwers, G. Y., Esnaola, N. F., Do, K.-A., Belghiti, J., Mirza, N., Curley, S. A., Ellis, L. M., Regimbeau, J.-M., Rashid, A., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.6.1527 · Cited by 700 · cited 1×
“Therefore, the resectability for HCC should not be decided upon according to tumor size (125-127).”
BackgroundSmith, H. S. (2009) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)60750-7 · Cited by 696 · cited 2×
“Therefore, careful selection, and dosage and interval adjustment of drugs are required according to the liver metabolism of each opioid (476, 483).”
BackgroundPortal Vein Embolization Before Right Hepatectomy: Prospective Clinical Trial
Farges, O., Belghiti, J., Kianmanesh, R., Marc Regimbeau, J., Santoro, R., Vilgrain, V., Denys, A., & Sauvanet, A. (2003) · Annals of Surgery · doi:10.1097/01.sla.0000048447.16651.7b · Cited by 676 · cited 1×
“org Some reports assert that portal vein embolization before extensive hepatic resection might induce compensatory hypertrophy of the residual liver and reduce the risk of surgery, especially in cases with liver cirrhosis; nonetheless, these are largely debatable (112, 113).”
BackgroundHepatic Resection Versus Transplantation for Hepatocellular Carcinoma
IWATSUKI, S., STARZL, T. E., SHEAHAN, D. G., YOKOYAMA, I., DEMETRIS, A. J., TODO, S., TZAKIS, A. G., VAN THIEL, D. H., CARR, B., SELBY, R., et al. (1991) · Annals of Surgery · doi:10.1097/00000658-199109000-00005 · Cited by 669 · cited 1×
“The application of broad selection criteria in the early history of LT resulted in very poor outcomes, with a 5-year survival less than 40%; there was even a time when LT was relatively contraindicated (158, 159).”
BackgroundRoayaie, S., Blume, I. N., Thung, S. N., Guido, M., Fiel, M., Hiotis, S., Labow, D. M., Llovet, J. M., & Schwartz, M. E. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.06.003 · Cited by 660 · cited 2×
“The 5-year recurrence rate following hepatic resection is up to 70% and is due to intrahepatic metastases and/or de novo carcinogenesis (96, 423, 499, 500).”
BackgroundHepatic insufficiency and mortality in 1,059 noncirrhotic patients undergoing major hepatectomy
Mullen, J. T., Ribero, D., Reddy, S. K., Donadon, M., Zorzi, D., Gautam, S., Abdalla, E. K., Curley, S. A., Capussotti, L., Clary, B. M., et al. (2007) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2006.12.032 · Cited by 660 · cited 1×
“Nevertheless, major hepatic resection should be considered with caution, because hepatic regeneration power gradually decreases with age (128-130).”
BackgroundPharmacokinetics and dosage adjustment in patients with hepatic dysfunction
Verbeeck, R. K. (2008) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-008-0553-z · Cited by 652 · cited 1×
“As most HCC patients have chronic liver disease and/or liver cirrhosis, their drug metabolism may be altered according to the degree of liver dysfunction (460).”
BackgroundSangro, B., Carpanese, L., Cianni, R., Golfieri, R., Gasparini, D., Ezziddin, S., Paprottka, P. M., Fiore, F., Van Buskirk, M., Bilbao, J. I., et al. (2011) · Hepatology · doi:10.1002/hep.24451 · Cited by 652 · cited 2×
“7 months, respectively; the difference was also statistically significant (312, 313).”
BackgroundDecreased Incidence of Hepatocellular Carcinoma in Hepatitis B Vaccinees: A 20-Year Follow-up Study
Chang, M.-H., You, S.-L., Chen, C.-J., Liu, C.-J., Lee, C.-M., Lin, S.-M., Chu, H.-C., Wu, T.-C., Yang, S.-S., Kuo, H.-S., et al. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp288 · Cited by 635 · cited 1×
“org of HCC can be achieved by universal vaccination against HBV infection (20), encouragement of healthy lifestyles preventing obesity and alcohol abuse, and controlling metabolic conditions.”
BackgroundCainap, C., Qin, S., Huang, W.-T., Chung, I. J., Pan, H., Cheng, Y., Kudo, M., Kang, Y.-K., Chen, P.-J., Toh, H.-C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.3298 · Cited by 629
Sangiovanni, A., Prati, G. M., Fasani, P., Ronchi, G., Romeo, R., Manini, M., Del Ninno, E., Morabito, A., & Colombo, M. (2006) · Hepatology · doi:10.1002/hep.21176 · Cited by 628 · cited 1×
“HCC develops in 1–4% of cirrhotic patients annually (18) and eventually develops in approximately one-third of cirrhotic patients (19).”
BackgroundYeo, W., Chan, P. K. S., Zhong, S., Ho, W. M., Steinberg, J. L., Tam, J. S., Hui, P., Leung, N. W. Y., Zee, B., & Johnson, P. J. (2000) · Journal of Medical Virology · doi:10.1002/1096-9071(200011)62:3<299::aid-jmv1>3.0.co;2-0 · Cited by 627 · cited 1×
“, breast cancer, hematologic malignancies, and other solid cancers) (430, 432-435).”
BackgroundLin, S.-M., Lin, C.-J., Lin, C.-C., Hsu, C.-W., & Chen, Y.-C. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.09.003 · Cited by 609 · cited 5×
“The reported rates of tumor necrosis after PEIT range between 66% and 100% (249-251, 259).”
BackgroundResultInfluentialRisk of cancer after low doses of ionising radiation: retrospective cohort study in 15 countries
Cardis, E., Vrijheid, M., Blettner, M., Gilbert, E., Hakama, M., Hill, C., Howe, G., Kaldor, J., Muirhead, C. R., Schubauer-Berigan, M., et al. (2005) · BMJ · doi:10.1136/bmj.38499.599861.e0 · Cited by 608 · cited 1×
“In addition, studies of occupational radiation exposure suggest protracted 50–100 mSv exposure can increase cancer risk in humans (69-71).”
BackgroundMazzaferro, V., Bhoori, S., Sposito, C., Bongini, M., Langer, M., Miceli, R., & Mariani, L. (2011) · Liver Transplantation · doi:10.1002/lt.22365 · Cited by 593
Lin, S.-M., Lin, C.-J., Lin, C.-C., Hsu, C.-W., & Chen, Y.-C. (2005) · Gut · doi:10.1136/gut.2004.045203 · Cited by 592
Yeo, W., Mok, T. S., Zee, B., Leung, T. W. T., Lai, P. B. S., Lau, W. Y., Koh, J., Mo, F. K. F., Yu, S. C. H., Chan, A. T., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji315 · Cited by 590 · cited 1×
“Meanwhile, hematologic toxicities were significantly more frequent in PIAF group (406).”
BackgroundLewandowski, R. J., Kulik, L. M., Riaz, A., Senthilnathan, S., Mulcahy, M. F., Ryu, R. K., Ibrahim, S. M., Sato, K. T., Baker, T., Miller, F. H., et al. (2009) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.02695.x · Cited by 582 · cited 1×
“Transarterial radioembolization (TARE) using Yttrium-90 ((90)Y) appears to outperform TACE for downstaging HCC from UNOS T3 to T2, and downstaged patients show a statistically insignificant trend toward improved overall survival after LT (205).”
Chemoembolization for hepatocellular carcinoma
Bruix, J., Sala, M., & Llovet, J. M. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.09.032 · Cited by 569
Intrahepatic Recurrence After Resection of Hepatocellular Carcinoma Complicating Cirrhosis
BELGHITI, J., PANIS, Y., FAROES, O., BENHAMOU, J. P., & FEKETE, F. (1991) · Annals of Surgery · doi:10.1097/00000658-199108000-00004 · Cited by 562 · cited 1×
“As there recurrence rate 5 years after curative resection for HCC is very high at 70% (see “Liver Resection” section) (142, 423, 424), an effective adjuvant therapy is urgently required.”
BackgroundLiver Transplantation for Hepatocellular Carcinoma
Bismuth, H., Majno, P., & Adam, R. (1999) · Seminars in Liver Disease · doi:10.1055/s-2007-1007120 · Cited by 561
Poon, R. T.-P., Fan, S.-T., Lo, C.-M., Liu, C.-L., & Wong, J. (1999) · Annals of Surgery · doi:10.1097/00000658-199902000-00009 · Cited by 550 · cited 1×
“Tumorrelated risk factors for recurrence are associated with early recurrence and include tumor size and number, degree of differentiation, vascular invasion, serum AFP (if elevated preoperatively), insufficient resection margin, and nonanatomical resection (142, 146, 499-502).”
BackgroundWelzel, T. M., Graubard, B. I., Zeuzem, S., El-Serag, H. B., Davila, J. A., & McGlynn, K. A. (2011) · Hepatology · doi:10.1002/hep.24397 · Cited by 543 · cited 1×
“The risk factors for HCC are relatively well known (14, 15) and include chronic hepatitis B/C, liver cirrhosis, alcoholic liver disease, obesity- and fatty liver diseaserelated diabetes mellitus (15, 16), and aflatoxin (17).”
BackgroundColli, A., Fraquelli, M., Casazza, G., Massironi, S., Colucci, A., Conte, D., & Duca, P. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00467.x · Cited by 540 · cited 1×
“The overall sensitivities of ultrasound, dynamic CT, and dynamic MRI for the noninvasive diagnosis of HCC are 61–67%, 68–91%, and 81–100%, respectively (53-55).”
BackgroundSilva, M. A., Hegab, B., Hyde, C., Guo, B., Buckels, J. A. C., & Mirza, D. F. (2008) · Gut · doi:10.1136/gut.2008.149062 · Cited by 536 · cited 1×
“1%, the need for biopsy for patients with HCC curable by surgical resection is being challenged (65, 66).”
BackgroundYttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: A phase 2 study
Mazzaferro, V., Sposito, C., Bhoori, S., Romito, R., Chiesa, C., Morosi, C., Maccauro, M., Marchianò, A., Bongini, M., Lanocita, R., et al. (2013) · Hepatology · doi:10.1002/hep.26014 · Cited by 517 · cited 2×
“4%, and the median survival period was 15 months (311).”
BackgroundConverting Dose-Length Product to Effective Dose at CT
Huda, W., Ogden, K. M., & Khorasani, M. R. (2008) · Radiology · doi:10.1148/radiol.2483071964 · Cited by 513 · cited 1×
“X-ray radiation exposure after a 4-phase liver dynamic CT (74, 75).”
BackgroundYao, F. Y., Kerlan, R. K., Hirose, R., Davern, T. J., Bass, N. M., Feng, S., Peters, M., Terrault, N., Freise, C. E., Ascher, N. L., et al. (2008) · Hepatology · doi:10.1002/hep.22412 · Cited by 513 · cited 2×
“Some prospective studies suggest downstaging according to the Milan or UCSF criteria as a result of locoregional therapies achieves 5-year survival outcomes similar to those within the Milan or UCSF criteria (190, 201).”
BackgroundResultAlcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma
Marrero, J. A., Fontana, R. J., Fu, S., Conjeevaram, H. S., Su, G. L., & Lok, A. S. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2004.10.005 · Cited by 511 · cited 1×
“liver disease, associations between diabetes and obesity, with HCC were recently reported (39, 40).”
BackgroundQin, S., Bai, Y., Lim, H. Y., Thongprasert, S., Chao, Y., Fan, J., Yang, T.-S., Bhudhisawasdi, V., Kang, W. K., Zhou, Y., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.5643 · Cited by 500
Development of the AGREE II, part 1: performance, usefulness and areas for improvement
Brouwers, M. C., Kho, M. E., Browman, G. P., Burgers, J. S., Cluzeau, F., Feder, G., Fervers, B., Graham, I. D., Hanna, S. E., Makarski, J., et al. (2010) · Canadian Medical Association Journal · doi:10.1503/cmaj.091714 · Cited by 499 · cited 1×
“In addition to the contents, methodological validity was evaluated on the basis of the Appraisal of Guidelines for Research and Evaluation II instrument (5, 6).”
MethodTorzilli, G., Belghiti, J., Kokudo, N., Takayama, T., Capussotti, L., Nuzzo, G., Vauthey, J.-N., Choti, M. A., De Santibanes, E., Donadon, M., et al. (2013) · Annals of Surgery · doi:10.1097/sla.0b013e31828329b8 · Cited by 496 · cited 1×
“In addition, the 5-year overall and disease-free survival rates are 46–56% and 23–32%, respectively (88-90).”
BackgroundBrouwers, M. C., Kho, M. E., Browman, G. P., Burgers, J. S., Cluzeau, F., Feder, G., Fervers, B., Graham, I. D., Hanna, S. E., Makarski, J., et al. (2010) · Canadian Medical Association Journal · doi:10.1503/cmaj.091716 · Cited by 495 · cited 1×
“In addition to the contents, methodological validity was evaluated on the basis of the Appraisal of Guidelines for Research and Evaluation II instrument (5, 6).”
MethodAlifakioti, D., Daccord, C., Lachenal, Y., & Fitting, J.-W. (2014) · Respiration · doi:10.1159/000367814 · Cited by 495
Radiofrequency versus Microwave Ablation in a Hepatic Porcine Model
Wright, A. S., Sampson, L. A., WARNER, T. F. C. S., Mahvi, D. M., & Lee, F. T. (2005) · Radiology · doi:10.1148/radiol.2361031249 · Cited by 493 · cited 1×
“In addition, effective ablation can be expected even for tissues with low electrical conductivity, and the simultaneous application of multiple electrodes is technically feasible with this technique (280, 281).”
BackgroundMazzaferro, V., Battiston, C., Perrone, S., Pulvirenti, A., Regalia, E., Romito, R., Sarli, D., Schiavo, M., Garbagnati, F., Marchianò, A., et al. (2004) · Annals of Surgery · doi:10.1097/01.sla.0000143301.56154.95 · Cited by 491 · cited 2×
“org reported to reduce the dropout rate to 0–25% (173, 187).”
BackgroundBurrel, M., Reig, M., Forner, A., Barrufet, M., Lope, C. R. D., Tremosini, S., Ayuso, C., Llovet, J. M., Real, M. I., & Bruix, J. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.01.008 · Cited by 485
Shi, M., Guo, R.-P., Lin, X.-J., Zhang, Y.-Q., Chen, M.-S., Zhang, C.-Q., Lau, W. Y., & Li, J.-Q. (2007) · Annals of Surgery · doi:10.1097/01.sla.0000231758.07868.71 · Cited by 483 · cited 1×
“One prospective randomized trial shows that a resection margin > 2 cm leads to better outcomes after HCC resection (118).”
BackgroundAdverse Events During Radiofrequency Treatment of 582 Hepatic Tumors
de Baère, T., Risse, O., Kuoch, V., Dromain, C., Sengel, C., Smayra, T., Din, M. G. E., Letoublon, C., & Elias, D. (2003) · American Journal of Roentgenology · doi:10.2214/ajr.181.3.1810695 · Cited by 478 · cited 2×
“5%, and the major complication rate after RFA is < 5% (247, 254, 255).”
BackgroundCho, Y. K., Kim, J. K., Kim, M. Y., Rhim, H., & Han, J. K. (2009) · Hepatology · doi:10.1002/hep.22648 · Cited by 466 · cited 3×
“RFA and percutaneous ethanol injection therapy (PEIT) are the current standard local therapies, while others such as microwave ablation, laser ablation, cryoablation, acetic acid injection therapy, and high-intensity focused ultrasound are currently undergoing clinical trials.”
BackgroundInfluentialProlonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon
Di Bisceglie, A. M., Shiffman, M. L., Everson, G. T., Lindsay, K. L., Everhart, J. E., Wright, E. C., Lee, W. M., Lok, A. S., Bonkovsky, H. L., Morgan, T. R., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707615 · Cited by 465 · cited 2×
“Previous studies including Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) (30, 31) and Evaluation of PegIntron in Control of Hepatitis C Cirrhosis (EPIC) studies (32) show that maintenance therapy with pegylated-interferon in cirrhotic patients does not significantly decrease the incidence of HCC…”
BackgroundSala, M., Llovet, J. M., Vilana, R., Bianchi, L., Solé, M., Ayuso, C., Brú, C., & Bruix, J. (2004) · Hepatology · doi:10.1002/hep.20465 · Cited by 447
Stereotactic Body Radiotherapy for Primary Hepatocellular Carcinoma
Andolino, D. L., Johnson, C. S., Maluccio, M., Kwo, P., Tector, A. J., Zook, J., Johnstone, P. A. S., & Cardenes, H. R. (2011) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2011.04.011 · Cited by 442 · cited 3×
“In addition, EBRT can be considered a bridging treatment for patients awaiting LT (199, 200, 319).”
BackgroundDonor Morbidity After Living Donation for Liver Transplantation
Ghobrial, R. M., Freise, C. E., Trotter, J. F., Tong, L., Ojo, A. O., Fair, J. H., Fisher, R. A., Emond, J. C., Koffron, A. J., Pruett, T. L., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.04.018 · Cited by 438 · cited 1×
“The 5-year overall and disease-free survival rates of expanded indications beyond the Milan criteria for LDLTs exceed 80% and 70%, respectively (220-222).”
BackgroundA phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases
Schefter, T. E., Kavanagh, B. D., Timmerman, R. D., Cardenes, H. R., Baron, A., & Gaspar, L. E. (2005) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2005.01.002 · Cited by 436 · cited 1×
“For hypofractionated EBRT consisting of ≤ 10 fractions, the normal liver volume receiving < 15 Gy must be ≥ 700 mL (317) and the dose to the normal liver volume excluding the tumor must be limited to ≤ 28 Gy (corrected to 2 Gy per fraction-equivalent dose) (318).”
BackgroundRisk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma
Wu, J.-C., Huang, Y.-H., Chau, G.-Y., Su, C.-W., Lai, C.-R., Lee, P.-C., Huo, T.-I., Sheen, I.-J., Lee, S.-D., & Lui, W.-Y. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.07.009 · Cited by 435 · cited 1×
“recurrence, include cirrhosis, high serum HBV DNA level, and active hepatitis (59, 142-148).”
BackgroundSelection Criteria for Repeat Hepatectomy in Patients With Recurrent Hepatocellular Carcinoma
Minagawa, M., Makuuchi, M., Takayama, T., & Kokudo, N. (2003) · Annals of Surgery · doi:10.1097/01.sla.0000094549.11754.e6 · Cited by 429 · cited 2×
“The 5-year recurrence rate after hepatic resection of HCC ranges from 58% to 81%, and 80% to 95% of postoperative recurrences are intrahepatic (140).”
BackgroundForner, A., Ayuso, C., Varela, M., Rimola, J., Hessheimer, A. J., de Lope, C. R., Reig, M., Bianchi, L., Llovet, J. M., & Bruix, J. (2009) · Cancer · doi:10.1002/cncr.24050 · Cited by 426 · cited 2×
“Several clinical studies on HCC demonstrate that the RECIST criteria do not mirror the extent of tumor necrosis induced by interventional therapies or new molecular targeted drugs (374, 495).”
BackgroundLau, W., Leung, T., Ho, S., Chan, M., Machin, D., Lau, J., Chan, A., Yeo, W., Mok, T., Yu, S., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(98)06475-7 · Cited by 409
Livraghi, T., Bolondi, L., Lazzaroni, S., Marin, G., Morabito, A., Rapaccini, G. L., Salmi, A., & Torzilli, G. (1992) · Cancer · doi:10.1002/1097-0142(19920215)69:4<925::aid-cncr2820690415>3.0.co;2-g · Cited by 406 · cited 1×
“Local tumor progression rates after PEIT range between 24% and 34%, although there is no consensus on the definition of local tumor progression (275-277).”
BackgroundPomfret, E. A., Washburn, K., Wald, C., Nalesnik, M. A., Douglas, D., Russo, M., Roberts, J., Reich, D. J., Schwartz, M. E., Mieles, L., et al. (2010) · Liver Transplantation · doi:10.1002/lt.21999 · Cited by 393 · cited 2×
“org reported to reduce the dropout rate to 0–25% (173, 187).”
BackgroundRoayaie, S., Frischer, J. S., Emre, S. H., Fishbein, T. M., Sheiner, P. A., Sung, M., Miller, C. M., & Schwartz, M. E. (2002) · Annals of Surgery · doi:10.1097/00000658-200204000-00012 · Cited by 390 · cited 2×
“If the cutoff for the definition of a cure is a 5-year survival rate of 50% after LT in patients with HCC, the indications for LT could be expanded beyond the Milan criteria (178, 179).”
BackgroundYao, F. Y., Bass, N. M., Nikolai, B., Davern, T. J., Kerlan, R., Wu, V., Ascher, N. L., & Roberts, J. P. (2002) · Liver Transplantation · doi:10.1053/jlts.2002.34923 · Cited by 389
For the European EOB-study group, Hammerstingl, R., Huppertz, A., Breuer, J., Balzer, T., Blakeborough, A., Carter, R., Fusté, L. C., Heinz-Peer, G., Judmaier, W., et al. (2008) · European Radiology · doi:10.1007/s00330-007-0716-9 · Cited by 384 · cited 1×
“MRI using a hepatic cell-specific contrast medium is superior to CT for HCC detection, especially for small HCCs < 1 cm (106, 107).”
Hasegawa, K., Kokudo, N., Makuuchi, M., Izumi, N., Ichida, T., Kudo, M., Ku, Y., Sakamoto, M., Nakashima, O., Matsui, O., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2012.11.009 · Cited by 382 · cited 1×
“Meanwhile, the 3-/5-year cumulative recurrence rates after RFA or PEIT for ≤ 3 tumors < 3 cm in diameter are 57/72% and 64/77%, respectively (512, 513).”
BackgroundTodo, S., & Furukawa, H. (2004) · Annals of Surgery · doi:10.1097/01.sla.0000137129.98894.42 · Cited by 380 · cited 1×
“Major risk factors for recurrence after transplantation are tumor size and vascular invasion; other risk factors include tumor number, degree of differentiation, serum AFP level, and bilobar location of tumors (508-510).”
BackgroundKim, Y.-S., Lim, H. K., Rhim, H., Lee, M. W., Choi, D., Lee, W. J., Paik, S. W., Koh, K. C., Lee, J. H., Choi, M. S., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2012.09.020 · Cited by 372
Eguchi, S., Kanematsu, T., Arii, S., Okazaki, M., Okita, K., Omata, M., Ikai, I., Kudo, M., Kojiro, M., Makuuchi, M., et al. (2008) · Surgery · doi:10.1016/j.surg.2007.12.003 · Cited by 368 · cited 2×
“Although some reports suggest anatomical resection may be superior to nonanatomical resection by securing the resection margin and removing micro-metastases (116), further confirmation is required, because the results are inconsistent (117).”
BackgroundResultMazzaferro, V., Romito, R., Schiavo, M., Mariani, L., Camerini, T., Bhoori, S., Capussotti, L., Calise, F., Pellicci, R., Belli, G., et al. (2006) · Hepatology · doi:10.1002/hep.21415 · Cited by 367 · cited 1×
“(38) recently reported that while no treatment effect was apparent on early recurrence in HCVpositive patients, there was a significant benefit on late recurrence (HR, 0.”
BackgroundHow Much Remnant Is Enough in Liver Resection?
Guglielmi, A., Ruzzenente, A., Conci, S., Valdegamberi, A., & Iacono, C. (2012) · Digestive Surgery · doi:10.1159/000335713 · Cited by 365 · cited 1×
“Nevertheless, a remnant liver volume ≥ 40% is generally recommended in cirrhotic patients for safety (102).”
BackgroundRavaioli, M., Grazi, G. L., Piscaglia, F., Trevisani, F., Cescon, M., Ercolani, G., Vivarelli, M., Golfieri, R., D’Errico Grigioni, A., Panzini, I., et al. (2008) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2008.02409.x · Cited by 363 · cited 1×
“Some prospective studies suggest downstaging according to the Milan or UCSF criteria as a result of locoregional therapies achieves 5-year survival outcomes similar to those within the Milan or UCSF criteria (190, 201).”
ResultIncidence and Predictors of Hepatocellular Carcinoma in Patients With Cirrhosis
Ioannou, G. N., Splan, M. F., Weiss, N. S., McDonald, G. B., Beretta, L., & Lee, S. P. (2007) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2007.02.039 · Cited by 363 · cited 1×
“HCC develops in 1–4% of cirrhotic patients annually (18) and eventually develops in approximately one-third of cirrhotic patients (19).”
BackgroundSingal, A. G., Volk, M. L., Jensen, D., Di Bisceglie, A. M., & Schoenfeld, P. S. (2010) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.11.018 · Cited by 362
Significance of Resection Margin in Hepatectomy for Hepatocellular Carcinoma: A Critical Reappraisal
Poon, R. T.-P., Fan, S.-T., Ng, I. O.-L., & Wong, J. (2000) · Annals of Surgery · doi:10.1097/00000658-200004000-00014 · Cited by 357 · cited 1×
“Meanwhile, another study reports that the resection margin width is not important so long as a tumor-negative margin is guaranteed (119).”
BackgroundHwang, S., Lee, S.-G., Lee, Y.-J., Sung, K.-B., Park, K.-M., Kim, K.-H., Ahn, C.-S., Moon, D.-B., Hwang, G.-S., Kim, K.-M., et al. (2006) · Liver Transplantation · doi:10.1002/lt.20734 · Cited by 352 · cited 1×
“The outcomes of live donors (n = 2872 published cases) from Korea are excellent (223-228).”
BackgroundKang, J., Kim, M., Cho, C. K., Yang, K. M., Yoo, H. J., Kim, J. H., Bae, S. H., Jung, D. H., Kim, Lee, D. H., et al. (2012) · Cancer · doi:10.1002/cncr.27533 · Cited by 334
Liver and Intestine Transplantation in the United States, 1997–2006
Freeman, R. B., Steffick, D. E., Guidinger, M. K., Farmer, D. G., Berg, C. L., & Merion, R. M. (2008) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2008.02174.x · Cited by 333 · cited 1×
“The Organ Procurement and Transplantation Network/Scientific Registry of Transplant Recipients data regarding LT for HCC show a higher 3-year post-LT survival rate in patients who received ablative procedures before LT than those who did not regardless of pre-LT treatment modality (197).”
BackgroundLee, S.-G., Hwang, S., Moon, D.-B., Ahn, C.-S., Kim, K.-H., Sung, K.-B., Ko, G.-Y., Park, K.-M., Ha, T.-Y., & Song, G.-W. (2008) · Liver Transplantation · doi:10.1002/lt.21445 · Cited by 330
Luo, J., Guo, R.-P., Lai, E. C. H., Zhang, Y.-J., Lau, W. Y., Chen, M.-S., & Shi, M. (2011) · Annals of Surgical Oncology · doi:10.1245/s10434-010-1321-8 · Cited by 328 · cited 2×
“A recent prospective nonrandomized study on unresectable HCC patients with portal vein invasion shows more favorable survival outcomes for the TACEtreated group than the supportive treatment group (304).”
BackgroundKim, S. H., Kim, S. H., Lee, J., Kim, M. J., Jeon, Y. H., Park, Y., Choi, D., Lee, W. J., & Lim, H. K. (2009) · American Journal of Roentgenology · doi:10.2214/ajr.08.1262 · Cited by 311 · cited 1×
“MRI using a hepatic cell-specific contrast medium is superior to CT for HCC detection, especially for small HCCs < 1 cm (106, 107).”
Lalazar, G., Rund, D., & Shouval, D. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06465.x · Cited by 311 · cited 1×
“, breast cancer, hematologic malignancies, and other solid cancers) (430, 432-435).”
BackgroundStigliano, R., Marelli, L., Yu, D., Davies, N., Patch, D., & Burroughs, A. K. (2007) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2007.04.001 · Cited by 311 · cited 1×
“1%, the need for biopsy for patients with HCC curable by surgical resection is being challenged (65, 66).”
BackgroundYin, J., Li, N., Han, Y., Xue, J., Deng, Y., Shi, J., Guo, W., Zhang, H., Wang, H., Cheng, S., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.5896 · Cited by 307 · cited 1×
“(33) reported oral antiviral treatment against HBV significantly decreased HCC recurrence and HCC-related death after resection, with hazard ratios (HRs) of 0.”
BackgroundPharmacokinetics of Opioids in Liver Disease
Tegeder, I., L??tsch, J., & Geisslinger, G. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199937010-00002 · Cited by 306 · cited 1×
“The half-life of morphine is approximately twice as long in cirrhotic patients as that in healthy controls (484, 485).”
BackgroundChapman, W. C., Majella Doyle, M. B., Stuart, J. E., Vachharajani, N., Crippin, J. S., Anderson, C. D., Lowell, J. A., Shenoy, S., Darcy, M. D., & Brown, D. B. (2008) · Annals of Surgery · doi:10.1097/sla.0b013e31818a07d4 · Cited by 304 · cited 1×
“Downstaging of HCC with TACE may be possible in 24–63% of cases (178, 196, 202, 203).”
BackgroundChung, G. E., Lee, J.-H., Kim, H. Y., Hwang, S. Y., Kim, J. S., Chung, J. W., Yoon, J.-H., Lee, H.-S., & Kim, Y. J. (2011) · Radiology · doi:10.1148/radiol.10101058 · Cited by 304 · cited 1×
“When TACE is performed for HCC patients with good hepatic functions but portal vein tumor invasion, the risk of hepatic functional deterioration after TACE is reported to be acceptably low (300-302).”
BackgroundBrunello, F., Veltri, A., Carucci, P., Pagano, E., Ciccone, G., Moretto, P., Sacchetto, P., Gandini, G., & Rizzetto, M. (2008) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520701885481 · Cited by 302 · cited 2×
“In four RCTs comparing RFA and PEIT for patients with HCC (249-251, 259, 260), patients treated with RFA showed better local tumor response and overall survival outcomes than those treated with PEIT.”
BackgroundResultRisk of Major Liver Resection in Patients With Underlying Chronic Liver Disease: A Reappraisal
Farges, O., Malassagne, B., Flejou, J. F., Balzan, S., Sauvanet, A., & Belghiti, J. (1999) · Annals of Surgery · doi:10.1097/00000658-199902000-00008 · Cited by 301 · cited 1×
“However, Child-Pugh classification is an insufficient preoperative indicator of operability, because many patients can remain in Child-Pugh class A despite advanced cirrhosis (92, 93).”
BackgroundMakuuchi, M., Kokudo, N., Arii, S., Futagawa, S., Kaneko, S., Kawasaki, S., Matsuyama, Y., Okazaki, M., Okita, K., Omata, M., et al. (2008) · Hepatology Research · doi:10.1111/j.1872-034x.2007.00216.x · Cited by 294 · cited 1×
“The overall sensitivities of ultrasound, dynamic CT, and dynamic MRI for the noninvasive diagnosis of HCC are 61–67%, 68–91%, and 81–100%, respectively (53-55).”
BackgroundPain Management in the Cirrhotic Patient: The Clinical Challenge
Chandok, N., & Watt, K. D. S. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2009.0534 · Cited by 291 · cited 3×
“Therefore, careful selection, and dosage and interval adjustment of drugs are required according to the liver metabolism of each opioid (476, 483).”
BackgroundA prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation
Yao, F. Y., Hirose, R., LaBerge, J. M., Davern, T. J., Bass, N. M., Kerlan, R. K., Merriman, R., Feng, S., Freise, C. E., Ascher, N. L., et al. (2005) · Liver Transplantation · doi:10.1002/lt.20526 · Cited by 288
Llovet, J. M. (2002) · Gut · doi:10.1136/gut.50.1.123 · Cited by 287
Park, J.-W., Kim, J. H., Kim, S. K., Kang, K. W., Park, K. W., Choi, J.-I., Lee, W. J., Kim, C.-M., & Nam, B. H. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.055087 · Cited by 287 · cited 3×
“recurrence, include cirrhosis, high serum HBV DNA level, and active hepatitis (59, 142-148).”
BackgroundPompili, M., Saviano, A., de Matthaeis, N., Cucchetti, A., Ardito, F., Federico, B., Brunello, F., Pinna, A. D., Giorgio, A., Giulini, S. M., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.03.009 · Cited by 285 · cited 1×
“Meanwhile, the 3-/5-year cumulative recurrence rates after RFA or PEIT for ≤ 3 tumors < 3 cm in diameter are 57/72% and 64/77%, respectively (512, 513).”
BackgroundHospital Mortality of Major Hepatectomy for Hepatocellular Carcinoma Associated With Cirrhosis
Fan, S.-T. (1995) · Archives of Surgery · doi:10.1001/archsurg.1995.01430020088017 · Cited by 280 · cited 1×
“Although major hepatic resection is recommended only for patients with ICG-R15 ≤ 10%, some authors recently reported safely performing right hemihepatectomy even in patients with an ICG-R15 of 14% (95).”
BackgroundCho, Y. K., Kim, J. K., Kim, W. T., & Chung, J. W. (2010) · Hepatology · doi:10.1002/hep.23466 · Cited by 276 · cited 1×
“A recent decision model analysis shows there was no difference in the survival outcomes of patients with single HCC smaller than 2 cm between the combined strategy and resection monotherapy (266).”
BackgroundShiratori, Y., Shiina, S., Teratani, T., Imamura, M., Obi, S., Sato, S., Koike, Y., Yoshida, H., & Omata, M. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-4-200302180-00008 · Cited by 274 · cited 1×
“(37) report that the rates of second or third recurrence appeared to be lower in the interferon group than the untreated group.”
BackgroundRisk factors for intrahepatic recurrence in human small hepatocellular carcinoma
Adachi, E., Maeda, T., Matsumata, T., Shirabe, K., Kinukawa, N., Sugimachi, K., & Tsuneyoshi, M. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)90450-6 · Cited by 272 · cited 1×
“Tumorrelated risk factors for recurrence are associated with early recurrence and include tumor size and number, degree of differentiation, vascular invasion, serum AFP (if elevated preoperatively), insufficient resection margin, and nonanatomical resection (142, 146, 499-502).”
BackgroundRandomized controlled trial of interferon treatment for advanced hepatocellular carcinoma
Llovet, J. M., Sala, M., Castells, L., Suarez, Y., Vilana, R., Bianchi, L., Ayuso, C., Vargas, V., Rodés, J., & Bruix, J. (2000) · Hepatology · doi:10.1002/hep.510310111 · Cited by 271 · cited 1×
“In addition, octreotide (402, 403), interferon (404), and tamoxifen (405)”
BackgroundVilana, R., Bruix, J., Bru, C., Ayuso, C., Solé, M., & Rodés, J. (1992) · Hepatology · doi:10.1002/hep.1840160212 · Cited by 270 · cited 1×
“Local tumor progression rates after PEIT range between 24% and 34%, although there is no consensus on the definition of local tumor progression (275-277).”
BackgroundAging Reduces Proliferative Capacities of Liver by Switching Pathways of C/EBPα Growth Arrest
Iakova, P., Awad, S. S., & Timchenko, N. A. (2003) · Cell · doi:10.1016/s0092-8674(03)00318-0 · Cited by 269 · cited 1×
“Nevertheless, major hepatic resection should be considered with caution, because hepatic regeneration power gradually decreases with age (128-130).”
BackgroundFuks, D., Dokmak, S., Paradis, V., Diouf, M., Durand, F., & Belghiti, J. (2012) · Hepatology · doi:10.1002/hep.24680 · Cited by 268
Predictive factors for postoperative recurrence of hepatocellular carcinoma
Okada, S., Shimada, K., Yamamoto, J., Takayama, T., Kosuge, T., Yamasaki, S., Sakamoto, M., & Hirohashi, S. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90419-7 · Cited by 268 · cited 2×
“The 5-year recurrence rate following hepatic resection is up to 70% and is due to intrahepatic metastases and/or de novo carcinogenesis (96, 423, 499, 500).”
BackgroundIoannou, G. N., Perkins, J. D., & Carithers, R. L. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.02.013 · Cited by 264 · cited 1×
“Some studies chose a 5-year survival rate cutoff of 70%, because it is similar to the rate expected for patients undergoing LT for noncancerous conditions and liver grafts from deceased donors (180-182).”
BackgroundSarasin, F. P., Majno, P. E., Llovet, J. M., Bruix, J., Mentha, G., & Hadengue, A. (2001) · Hepatology · doi:10.1053/jhep.2001.23311 · Cited by 263
Miyayama, S., Matsui, O., Yamashiro, M., Ryu, Y., Kaito, K., Ozaki, K., Takeda, T., Yoneda, N., Notsumata, K., Toya, D., et al. (2007) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2006.12.004 · Cited by 260 · cited 9×
“Downstaging of HCC with TACE may be possible in 24–63% of cases (178, 196, 202, 203).”
BackgroundInfluentialSanuki, N., Takeda, A., Oku, Y., Mizuno, T., Aoki, Y., Eriguchi, T., Iwabuchi, S., & Kunieda, E. (2014) · Acta Oncologica · doi:10.3109/0284186x.2013.820342 · Cited by 260 · cited 2×
“In particular, stereotactic ablative radiation therapy for the treatment of ≤ 3 lesions and lesions with a cumulative diameter ≤ 6 cm results in local control rates exceeding 90% (319, 323-325).”
BackgroundPredictors of Survival After Resection of Early Hepatocellular Carcinoma
Nathan, H., Schulick, R. D., Choti, M. A., & Pawlik, T. M. (2009) · Annals of Surgery · doi:10.1097/sla.0b013e3181a38eb5 · Cited by 258 · cited 1×
“recurrence, include cirrhosis, high serum HBV DNA level, and active hepatitis (59, 142-148).”
BackgroundPractice guidelines for management of hepatocellular carcinoma 2009
Korean Liver Cancer Study Group and National Cancer Center, K. (2009) · The Korean Journal of Hepatology · doi:10.3350/kjhep.2009.15.3.391 · Cited by 257
Transcatheter Therapy for Hepatic Malignancy: Standardization of Terminology and Reporting Criteria
Brown, D. B., Gould, J. E., Gervais, D. A., Goldberg, S. N., Murthy, R., Millward, S. F., Rilling, W. S., Geschwind, J.-F. S., Salem, R., Vedantham, S., et al. (2009) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2009.04.021 · Cited by 257
Coffee Reduces Risk for Hepatocellular Carcinoma: An Updated Meta-analysis
Bravi, F., Bosetti, C., Tavani, A., Gallus, S., & La Vecchia, C. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.04.039 · Cited by 253 · cited 1×
“(41) reported that coffee consumption reduced the RR of HCC compared to no coffee consumption: the summary RR was 0.”
BackgroundVibert, E., Azoulay, D., Hoti, E., Iacopinelli, S., Samuel, D., Salloum, C., Lemoine, A., Bismuth, H., Castaing, D., & Adam, R. (2010) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.02750.x · Cited by 248 · cited 2×
“AFP increasing > 15 μg/L/ mo while waiting for LT is the most relevant preoperative prognostic factor for low overall survival and disease-free survival (185).”
BackgroundNon-steroidal anti-inflammatory drugs: What is the actual risk of liver damage?
Bessone, F. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i45.5651 · Cited by 248 · cited 1×
“Indeed, roughly 10% of total drug-induced hepatotoxicity cases are related to NSAIDs (478), and NSAID-induced liver injury is well documents (466, 479).”
BackgroundLiu, C. L., Fan, S. T., Cheung, S. T., Lo, C. M., Ng, I. O., & Wong, J. (2006) · Annals of Surgery · doi:10.1097/01.sla.0000225095.18754.45 · Cited by 245 · cited 1×
“The anterior approach, which is often used for the resection of large tumors, is associated with less bleeding, a lower transfusion rate, and better survival in one prospective study (139).”
BackgroundIs Portal Hypertension a Contraindication to Hepatic Resection?
Cucchetti, A., Ercolani, G., Vivarelli, M., Cescon, M., Ravaioli, M., Ramacciato, G., Grazi, G. L., & Pinna, A. D. (2009) · Annals of Surgery · doi:10.1097/sla.0b013e3181b977a5 · Cited by 244
Andersson, K. L., Salomon, J. A., Goldie, S. J., & Chung, R. T. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.08.005 · Cited by 242 · cited 1×
“, abdominal ultrasound and serum α-fetoprotein [AFP]) is warranted in these high-risk groups (42, 43).”
BackgroundRadiation therapy for hepatocellular carcinoma: From palliation to cure
Hawkins, M. A., & Dawson, L. A. (2006) · Cancer · doi:10.1002/cncr.21811 · Cited by 241 · cited 2×
“The reported overall response rates and median survival after EBRT are 40–90% and 10–25 months, respectively (315).”
BackgroundIto, T., Takada, Y., Ueda, M., Haga, H., Maetani, Y., Oike, F., Ogawa, K., Sakamoto, S., Ogura, Y., Egawa, H., et al. (2007) · Liver Transplantation · doi:10.1002/lt.21281 · Cited by 240
Shibata, T., Isoda, H., Hirokawa, Y., Arizono, S., Shimada, K., & Togashi, K. (2009) · Radiology · doi:10.1148/radiol.2523081676 · Cited by 239 · cited 1×
“overall survival rates between combined treatment and RFA monotherapy is < 10% for tumors smaller than 3 cm (267, 268) but is much greater for HCCs 3–5 cm in diameter (268).”
BackgroundPawlik, T. M., Poon, R. T., Abdalla, E. K., Ikai, I., Nagorney, D. M., Belghiti, J., Kianmanesh, R., Oi-Lin Ng, I., Curley, S. A., Yamaoka, Y., et al. (2005) · Surgery · doi:10.1016/j.surg.2004.12.012 · Cited by 235 · cited 1×
“In patients with less hepatic fibrosis or those with a well-differentiated HCC of low Edmondson-Steiner grade, the 5-year survival rate after resection of HCC with major vascular invasion is reported to be ≥ 20% (135).”
BackgroundSacco, R., Bargellini, I., Bertini, M., Bozzi, E., Romano, A., Petruzzi, P., Tumino, E., Ginanni, B., Federici, G., Cioni, R., et al. (2011) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2011.07.002 · Cited by 234 · cited 1×
“In another RCT, there was no significant difference between the two treatments with respect to tumor response, time to progression, or survival period (307).”
BackgroundSont, W. N., Zielinski, J. M., Ashmore, J. P., Jiang, H., Krewski, D., Fair, M. E., Band, P. R., & Létourneau, E. G. (2001) · American Journal of Epidemiology · doi:10.1093/aje/153.4.309 · Cited by 231 · cited 1×
“In addition, studies of occupational radiation exposure suggest protracted 50–100 mSv exposure can increase cancer risk in humans (69-71).”
BackgroundToso, C., Trotter, J., Wei, A., Bigam, D. L., Shah, S., Lancaster, J., Grant, D. R., Greig, P. D., Shapiro, A. M. J., & Kneteman, N. M. (2008) · Liver Transplantation · doi:10.1002/lt.21484 · Cited by 230 · cited 1×
“Microvascular invasion in pretransplant biopsy, tumor volume, and AFP levels are also considered in the expanded indications for LT (185, 186).”
BackgroundGeorgiades, C. S., Hong, K., D'Angelo, M., & Geschwind, J.-F. H. (2005) · Journal of Vascular and Interventional Radiology · doi:10.1097/01.rvi.0000182185.47500.7a · Cited by 226 · cited 1×
“When TACE is performed for HCC patients with good hepatic functions but portal vein tumor invasion, the risk of hepatic functional deterioration after TACE is reported to be acceptably low (300-302).”
BackgroundFukumitsu, N., Sugahara, S., Nakayama, H., Fukuda, K., Mizumoto, M., Abei, M., Shoda, J., Thono, E., Tsuboi, K., & Tokuuye, K. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2008.10.073 · Cited by 225 · cited 1×
“Proton therapy for HCC results in a 2-year local control rate from 75% to 96% and a 5-year survival rate from 23% to 44% (199, 326-329).”
Background
Cited by
Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study
Park, J., Chen, M., Colombo, M., Roberts, L. R., Schwartz, M., Chen, P., Kudo, M., Johnson, P., Wagner, S., Orsini, L. S., et al. (2015) · Liver International · doi:10.1111/liv.12818 · Cited by 1,245
Chernyak, V., Fowler, K. J., Kamaya, A., Kielar, A. Z., Elsayes, K. M., Bashir, M. R., Kono, Y., Do, R. K., Mitchell, D. G., Singal, A. G., et al. (2018) · Radiology · doi:10.1148/radiol.2018181494 · Cited by 1,152
Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis
Tang, A., Hallouch, O., Chernyak, V., Kamaya, A., & Sirlin, C. B. (2018) · Abdominal Radiology · doi:10.1007/s00261-017-1209-1 · Cited by 480
Korean Liver Cancer Association, K., & National Cancer Center, N. (2019) · Gut and Liver · doi:10.5009/gnl19024 · Cited by 391
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0294 · Cited by 343
Metadata
- Authors
- Korean Liver Cancer Study Group (KLCSG), & National Cancer Center, K. (.
- Venue
- Korean Journal of Radiology
- Publisher
- XMLink
- Published
- 2015
- Volume
- 16
- Issue
- 3
- Pages
- 465
- ISSN
- 1229-6929 (ISSN-L)
- 2005-8330
- OpenAlex
- W2561341815
- Cited by
- 201
- References
- 367
- FWCI
- 15.18
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.